Cargando…
Disease monitoring of biologic treatment in IBD: early impact and future implications of COVID-19 pandemic
COVID-19 has dominated life in 2020 with, at the time of writing, over 4.9M global cases and >320 000 deaths. The impact has been most intensely felt in acute and critical care environments. However, with most UK elective work postponed, laboratory testing of faecal calprotectin halted due to pot...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8231430/ https://www.ncbi.nlm.nih.gov/pubmed/34249322 http://dx.doi.org/10.1136/flgastro-2020-101563 |
_version_ | 1783713423163392000 |
---|---|
author | Shields, Stephanie Dunlop, Allan Seenan, John Paul Macdonald, Jonathan |
author_facet | Shields, Stephanie Dunlop, Allan Seenan, John Paul Macdonald, Jonathan |
author_sort | Shields, Stephanie |
collection | PubMed |
description | COVID-19 has dominated life in 2020 with, at the time of writing, over 4.9M global cases and >320 000 deaths. The impact has been most intensely felt in acute and critical care environments. However, with most UK elective work postponed, laboratory testing of faecal calprotectin halted due to potential risk of viral transmission and non-emergency endoscopies and surgeries cancelled, the secondary impact on chronic illnesses such as inflammatory bowel disease (IBD) is becoming apparent. Data from the Scottish Biologic Therapeutic Drug Monitoring (TDM) service shows a dramatic drop in TDM testing since the pandemic onset. April 2020 saw a 75.6% reduction in adalimumab testing and a 36.2% reduction in infliximab testing when compared with February 2020 data, a reduction coinciding with the widespread cancellation of outpatient and elective activity. It is feared that disruption to normal patterns of care and disease monitoring of biologic patients could increase the risk of disease flare and adverse clinical outcomes. Urgent changes in clinical practice have been instigated to mitigate the effects of the pandemic on routine clinical care. Further transformations are needed to maintain safe, effective, patient-centred IBD care in the future. |
format | Online Article Text |
id | pubmed-8231430 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-82314302021-07-09 Disease monitoring of biologic treatment in IBD: early impact and future implications of COVID-19 pandemic Shields, Stephanie Dunlop, Allan Seenan, John Paul Macdonald, Jonathan Frontline Gastroenterol Colorectal COVID-19 has dominated life in 2020 with, at the time of writing, over 4.9M global cases and >320 000 deaths. The impact has been most intensely felt in acute and critical care environments. However, with most UK elective work postponed, laboratory testing of faecal calprotectin halted due to potential risk of viral transmission and non-emergency endoscopies and surgeries cancelled, the secondary impact on chronic illnesses such as inflammatory bowel disease (IBD) is becoming apparent. Data from the Scottish Biologic Therapeutic Drug Monitoring (TDM) service shows a dramatic drop in TDM testing since the pandemic onset. April 2020 saw a 75.6% reduction in adalimumab testing and a 36.2% reduction in infliximab testing when compared with February 2020 data, a reduction coinciding with the widespread cancellation of outpatient and elective activity. It is feared that disruption to normal patterns of care and disease monitoring of biologic patients could increase the risk of disease flare and adverse clinical outcomes. Urgent changes in clinical practice have been instigated to mitigate the effects of the pandemic on routine clinical care. Further transformations are needed to maintain safe, effective, patient-centred IBD care in the future. BMJ Publishing Group 2020-09-30 /pmc/articles/PMC8231430/ /pubmed/34249322 http://dx.doi.org/10.1136/flgastro-2020-101563 Text en © Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ. https://bmj.com/coronavirus/usageThis article is made freely available for use in accordance with BMJ’s website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained. |
spellingShingle | Colorectal Shields, Stephanie Dunlop, Allan Seenan, John Paul Macdonald, Jonathan Disease monitoring of biologic treatment in IBD: early impact and future implications of COVID-19 pandemic |
title | Disease monitoring of biologic treatment in IBD: early impact and future implications of COVID-19 pandemic |
title_full | Disease monitoring of biologic treatment in IBD: early impact and future implications of COVID-19 pandemic |
title_fullStr | Disease monitoring of biologic treatment in IBD: early impact and future implications of COVID-19 pandemic |
title_full_unstemmed | Disease monitoring of biologic treatment in IBD: early impact and future implications of COVID-19 pandemic |
title_short | Disease monitoring of biologic treatment in IBD: early impact and future implications of COVID-19 pandemic |
title_sort | disease monitoring of biologic treatment in ibd: early impact and future implications of covid-19 pandemic |
topic | Colorectal |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8231430/ https://www.ncbi.nlm.nih.gov/pubmed/34249322 http://dx.doi.org/10.1136/flgastro-2020-101563 |
work_keys_str_mv | AT shieldsstephanie diseasemonitoringofbiologictreatmentinibdearlyimpactandfutureimplicationsofcovid19pandemic AT dunlopallan diseasemonitoringofbiologictreatmentinibdearlyimpactandfutureimplicationsofcovid19pandemic AT seenanjohnpaul diseasemonitoringofbiologictreatmentinibdearlyimpactandfutureimplicationsofcovid19pandemic AT macdonaldjonathan diseasemonitoringofbiologictreatmentinibdearlyimpactandfutureimplicationsofcovid19pandemic |